August 20, 2014 12:42 PM ET

Biotechnology

Company Overview of MacroGenics, Inc.

Company Overview

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Its products include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast, gastroesophageal, bladder, and other cancers; MGA271, an Fc-optimized monoclonal antibody for various solid tumor types; MGD006, a humanized dual affinity re-targeting (DART) molecule for the treatment of hematologic cancers; and MGD007, a DART protein to treat colorectal cancer. The company’s products also comprise Teplizumab, a humanized anti-CD3 monoclon...

9640 Medical Center Drive

Rockville, MD 20850

United States

Founded in 2000

166 Employees

Phone:

301-251-5172

Fax:

301-251-5321

Key Executives for MacroGenics, Inc.

Chief Executive Officer
Age: 61
Total Annual Compensation: $456.1K
Chief Financial Officer
Age: 46
Total Annual Compensation: $306.7K
Senior Vice President of Research
Age: 60
Total Annual Compensation: $298.1K
Senior Vice President of Clinical Development
Age: 52
Total Annual Compensation: $148.6K
Consultant
Age: 53
Total Annual Compensation: $357.7K
Compensation as of Fiscal Year 2013.

MacroGenics, Inc. Key Developments

MacroGenics, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Update on Corporate Progress

MacroGenics, Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $9,220,000, loss from operations of $12,260,000, net comprehensive loss of $12,259,000 or $0.44 per basic and diluted share compared to total revenues of $12,298,000, loss from operations of $254,000, net comprehensive loss of $294,000 or $0.24 per diluted share a year ago. For the six months, the company reported total revenues of $23,939,000, loss from operations of $15,368,000, net comprehensive loss of $15,367,000 or $0.57 per basic and diluted share compared to total revenues of $22,896,000, loss from operations of $3,586,000, net comprehensive loss of $3,660,000 or $3.00 per diluted share a year ago. The company provided update on corporate progress. Margetuximab is an Fc-optimized monoclonal antibody that targets HER2-expressing tumors, including gastroesophageal, breast and other cancers. Recent highlights include: Completed Phase 1 Enrollment: MacroGenics has completed enrollment of its three intermittent dosing cohorts that explored dosing up to 18 mg/kg every three weeks. Margetuximab continues to exhibit both a favorable safety profile and evidence of single-agent activity in refractory HER-2 positive cancer patients. Enrollment in the Company's Phase 2a metastatic breast cancer study continues and planning for the Phase 3 MAGENTA study for gastroesophageal cancer is ongoing. MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules involved in immune regulation. Recent highlights include: Planned Phase 1 Expansion: MacroGenics expects to complete enrollment of the first three dose-expansion cohorts of its MGA271 Phase 1 clinical trial by the end of 2014. The company plans to initiate multiple additional monotherapy expansion cohorts across various solid tumor types beginning in the second half of this year. MacroGenics also plans to initiate further studies of MGA271 in combination with other therapies in 2015. MGD006 is a Dual-Affinity Re-Targeting (DART) molecule that recognizes both CD123 and CD3. CD123, the interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells. The primary mechanism of action of MGD006 is its ability to redirect T cells, via their CD3 component, to kill CD123-expressing cells. Recent highlights include: Dosing Initiated in Phase 1 Clinical Study: During the second quarter of 2014, MacroGenics announced that the first patient had received drug in a Phase 1 study of MGD006 for the treatment of acute myeloid leukemia. MGD006 represents the first DART molecule to enter the clinic. MGD007 is a DART molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3. gpA33 is expressed by approximately 95% of primary and metastatic human colorectal cancers, including cancer stem cells that are thought to be responsible for tumor recurrence and metastasis. The primary mechanism of action of MGD007 is its ability to redirect T cells, via their CD3 component, to kill gpA33-expressing colon cancer cells. MGD010 is a DART molecule that simultaneously targets CD32B and CD79B, which are two B cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. Recent highlights include: Strategic Alliance formed with Takeda: During the second quarter of 2014, MacroGenics entered into an option agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of MGD010. This transaction represents the Company's fifth major corporate collaboration around its DART platform. MacroGenics received a $15 million upfront payment and is eligible to receive an additional license option fee and an early development milestone that together would total $18 million. Assuming successful development and commercialization of MGD010, MacroGenics could receive up to an additional $468.5 million in milestone payments and double-digit royalties on any global net sales. MacroGenics has the option to co-promote MGD010 in the United States and may participate in funding late-stage development of the program in exchange for a share of North American profits. Pre-Clinical Data Presented at IMMUNOLOGY 2014: At the American Association of Immunologists' Annual Meeting in May, MacroGenics presented pre-clinical data on MGD010, demonstrating the molecule's ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders. MGD010 also was shown to inhibit the development of graft-versus-host disease in a humanized mouse model, a system amenable to ascertain the activity of immunomodulatory interventions.

MacroGenics, Inc. to Report Q2, 2014 Results on Aug 05, 2014

MacroGenics, Inc. announced that they will report Q2, 2014 results at 8:05 PM, GMT Standard Time on Aug 05, 2014

MacroGenics, Inc., Q2 2014 Earnings Call, Aug 05, 2014

MacroGenics, Inc., Q2 2014 Earnings Call, Aug 05, 2014

Similar Private Companies By Industry

Company Name Region
Caisson Laboratories, Inc. United States
Oncobiologics, Inc. United States
ImmunGene Inc. United States
Sequenta, Inc. United States
MesoBio LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MacroGenics, Inc., please visit www.macrogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.